Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase I Dose Escalation Trial of MVA-BN-PRO in Men With Androgen-Insensitive Prostate Cancer

Next Previous
Search
Trial Profile

An Open-Label, Phase I Dose Escalation Trial of MVA-BN-PRO in Men With Androgen-Insensitive Prostate Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MVA-BN-PRO (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Bavarian Nordic

    • Most Recent Events

    • 13 Feb 2013 Results will be presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium according to a Bavarian Nordic media release. Results were also briefly summarised in the media release.
    • 25 Jan 2012 Additional lead trial investigator (Bandman O) identified as reported by ClinicalTrials.gov.
    • 27 Jun 2011 Planned end date changed from 1 Aug 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top